CDK 4/6 inhibitors (CDK4/6i) for metastatic breast cancer (mBC): The Likelihood of being Helped or Harmed (LHH) as a patient-centred tool to assess clinical impact and safety

被引：0
|
作者：
Mastrantoni, L. [1 ]
Orlandi, A. [2 ]
Palazzo, A. [2 ]
Garufi, G. [1 ]
Fabi, A. [3 ]
Daniele, G. [4 ]
Giannarelli, D. [5 ]
Tortora, G. [6 ]
Bria, E. [6 ]
机构：
[1] Univ Cattolica Sacro Cuore, Med Oncol Dept, Rome, Italy
[2] Fdn Policlin Univ Agostino Gemelli IRCCS, Med Oncol, Rome, Italy
[3] Fdn Policlin Univ Agostino Gemelli IRCCS, Dept Women Children & Publ Hlth Sci, Precis Med Breast Unit, Sci Directorate, Rome, Italy
[4] Fdn Policlin Univ Agostino Gemelli IRCCS, UOC Phase I, Rome, Italy
[5] Fdn Policlin Univ Agostino Gemelli IRCCS, Biostat, Rome, Italy
[6] Fdn Policlin Univ Agostino Gemelli IRCCS, Med Oncol Unit, Rome, Italy
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期
关键词：
D O I：
10.1016/j.annonc.2022.07.273
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
234P
引用
收藏
页码：S644 / S644
页数：1
相关论文
共 50 条
  • [41] IMMUNOLOGICAL MECHANISMS OF RESISTANCE TO CDK4/CDK6 INHIBITORS IN BREAST CANCER
    Petroni, Giulia
    Gouin, Kenneth
    Martinez, Aitziber Buque
    Knott, Simon
    Formenti, Silvia
    Galluzzi, Lorenzo
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A763 - A763
  • [42] The emerging role of CDK4/6i in HER2-positive breast cancer
    O'Sullivan, Ciara C.
    Suman, Vera J.
    Goetz, Matthew P.
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2019, 11
  • [43] An Overview of the Roles of CDK4/6 Inhibitors in Metastatic Breast Cancer Elderly Patients
    Pacilio, C. A. R. M. E. N.
    Rosati, G. E. R. A. R. D. O.
    Crispo, A. N. N. A.
    Bimonte, S. A. B. R. I. N. A.
    DI Rella, F. R. A. N. C. E. S. C. A.
    Nuzzo, F. R. A. N. C. E. S. C. O.
    DE Laurentiis, M. I. C. H. E. L. I. N. O.
    IN VIVO, 2023, 37 (04): : 1445 - 1449
  • [44] Survival according to early ctDNA dynamics in advanced breast cancer (ABC) treated with endocrine therapy (ET) and a CDK4/6 inhibitor (CDK4/6i)
    Martinez Saez, O.
    Felip Falgas, E.
    Cappelletti, M.
    Tolosa, P.
    Braso-Maristany, F.
    Sanfeliu Torres, E.
    Pascual, T.
    Chic, N.
    Vidal, M.
    Adamo, B.
    Munoz, M.
    Faull, I.
    Odegaard, J.
    Patel, G.
    McEwen, R.
    Carroll, D.
    Ciruelos, E. M.
    Generali, D. G.
    Margeli Vila, M.
    Prat, A.
    ANNALS OF ONCOLOGY, 2022, 33 : S127 - S128
  • [45] Impact of metastases directed radiation therapy on CDK4/6 inhibitors treatment for metastatic breast cancer
    Meattini, I.
    Visani, L.
    Ratosa, I.
    Saieva, C.
    Ribnikar, D.
    Scoccimarro, E.
    Becherini, C.
    Orazem, M.
    Stocchi, G.
    Bellini, C.
    Lorenzetti, V.
    Orsatti, C.
    Angelini, L.
    Desideri, I.
    Scotti, V.
    Morandi, A.
    Marinko, T.
    Livi, L.
    ANNALS OF ONCOLOGY, 2021, 32 : S465 - S465
  • [46] Clinical effectiveness of CDK4/6 inhibitors in HER2-low metastatic breast cancer
    Zhang, Frank
    Mesias, Jesus Anampa
    CANCER RESEARCH, 2024, 84 (09)
  • [47] Clinical development of CDK4/6 inhibitor for breast cancer
    Iwata, Hiroji
    BREAST CANCER, 2018, 25 (04) : 402 - 406
  • [48] Clinical development of CDK4/6 inhibitor for breast cancer
    Hiroji Iwata
    Breast Cancer, 2018, 25 : 402 - 406
  • [49] Safety and efficacy of concomitant radiation and CDK4/6 inhibitors in breast cancer patients
    Visani, L.
    Ratosa, I.
    Scoccimarro, E.
    Becherini, C.
    Saieva, C.
    Desideri, I.
    Scotti, V.
    Ozarem, M.
    Ribnikar, D.
    Aquilano, M.
    Cerbai, C.
    Orzalesi, L.
    Bernini, M.
    Sanchez, L.
    Nori, J.
    Bianchi, S.
    Meattini, I.
    Livi, L.
    RADIOTHERAPY AND ONCOLOGY, 2021, 161 : S44 - S45
  • [50] Treatment with CDK4/6 Inhibitor in a Patient with Metastatic Breast Cancer Causing Myelophthisis
    Dahake, Nikita
    Senchak, Jordan
    Nasibli, Jalil
    Incorvati, Jason
    CANCER RESEARCH, 2024, 84 (09)
12345